Rhythm Pharmaceuticals, Inc. (RYTM) Financials
RYTM Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 332.7 million | 163.0 million |
| 2023-09-30 | 354.2 million | 156.7 million |
| 2023-06-30 | 309.9 million | 127.7 million |
| 2023-03-31 | 345.7 million | 125.9 million |
RYTM Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -29.4 million | 8.7 million |
| 2023-09-30 | -29.3 million | 8.6 million |
| 2023-06-30 | -42.0 million | 8.9 million |
| 2023-03-31 | -36.5 million | 6.4 million |
RYTM Net Income
No data available :(
RYTM Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 275.8 million | - | 1.3 million |
| 2023-09-30 | 299.3 million | - | 1.4 million |
| 2023-06-30 | 253.6 million | 1.3 million | 1.6 million |
| 2023-03-31 | 294.6 million | 1.3 million | 1.8 million |
RYTM Shares Outstanding
RYTM Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 1000 | 29.9 million | 32.4 million | - |
| 2023-09-30 | 1000 | 33.6 million | 30.5 million | - |
| 2023-06-30 | 875000 | 33.5 million | 30.0 million | - |
| 2023-03-31 | 47000 | 37.9 million | 24.6 million | - |
RYTM Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 24.2 million | 3.2 million |
| 2023-09-30 | 22.5 million | 2.4 million |
| 2023-06-30 | 19.2 million | 2.2 million |
| 2023-03-31 | 11.5 million | 1.4 million |
RYTM
Price: $42.68
52 week price:
Earnings Per Share: -3.20 USD
P/E Ratio: -15.09
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 483700
Ebitda: -8.2 millionMarket Capitalization: 2.5 billion